Aldose reductase inhibition in the treatment of diabetic neuropathy: Where are we in 2004?

被引：39

作者：

Gabbay K.H. ^{[1
]}

机构：

[1] Baylor College of Medicine, H.B./A.B. Gordon Diabet. Res. Center, Houston, TX 77030-2399

来源：

Current Diabetes Reports | 2004年 / 4卷 / 6期

基金：

美国国家卫生研究院;

关键词：

Diabetic Neuropathy; Aldose Reductase; Sural Nerve; Polyol Pathway; Aldose Reductase Inhibition;

D O I：

10.1007/s11892-004-0047-z

中图分类号：

学科分类号：

摘要：

Diabetic neuropathy is a major complication of poorly controlled diabetes mellitus. Aldose reductase, the first enzyme of the polyol pathway, is thought to play a role in initiating the metabolic damage to peripheral nerves during hyperglycemia. Aldose reductase, inhibitors (ARIs) have been proposed to dampen the flux of glucose through the pathway during hyperglycemia; however, clinical trials in diabetic patients to demonstarate efficacy in the prevention or amelioration of diabetic neuropathy have failed thus far. Recent improved understanding of the pitfalls of past trials and some improved ARIs and clinical evaluation instruments show promise that success in the 20-plus year search for efficacious ARIs may soon be at hand. Copyright © 2004 by Current Science Inc.

引用

页码：405 / 408

页数：3

共 26 条

[1]

Kinoshita J.H., A thirty year journey in the polyol pathway, Exp. Eye Res., 50, pp. 567-573, (1990)

[2]

Buzney S.M., Frank R.N., Varma S.D., Et al., Aldose reductase in retinal mural cells, Invest. Ophthalmol. Vis. Sci., 16, pp. 392-396, (1977)

[3]

Robison W.G., Nagata M., Laver N., Et al., Diabetic-like retinopathy in raw prevented with an aldose reductase inhibitor, Invest. Ophthalmol. Vis. Sci., 30, pp. 2285-2292, (1989)

[4]

Gabbay K.H., Role of sorbitol pathway in neuropathy, Adv. Metab. Disord., 2, SUPPL. 2, pp. 417-432, (1973)

[5]

Gabbay K.H., Snider J., Nerve conduction defect in galactosefed rats, Diabetes, 21, pp. 295-300, (1972)

[6]

Judzewitsch R.G., Jaspan J.B., Polonsky K., Et al., Aldose reductase inhibition improves nerve conduction velocity in diabetic patients, N. Engl. J. Med., 308, pp. 119-125, (1983)

[7]

Mogensen C.E., The effect of blood pressure intervention on renal function in insulin-dependent diabetes, Diabet. Metab., 15, 5 PART 2, pp. 343-351, (1989)

[8]

Schleicher E.D., Olgemoller B., Glomerular changes in diabetes mellitus, Eur. J. Clin. Chem. Clin. Biochem., 30, pp. 635-640, (1992)

[9]

Pedersen M.M., Christiansen J.S., Mogensen C.E., Reduction of glomerular hyperfiltration in normoalbuminuric IDDM patients by six months of aldose reductase inhibition, Diabetes, 40, pp. 527-531, (1991)

[10]

Williamson J.R., Chang K., Tilton R.G., Et al., Increased vascular permeability in spontaneously diabetic BB/W rats and in rats with mild versus severe streptozocin-induced diabetes. Prevention by aldose reductase inhibitors and castration, Diabetes, 36, pp. 813-821, (1987)

← 1 2 3 →